Laigo Bio

Laigo Bio is a Dutch biotechnology company pioneering a novel class of targeted protein degradation therapeutics using its proprietary SureTAC (Surface Removal Targeting Chimeras) platform. Unlike traditional small-molecule degraders, SureTACs are bispecific antibodies that promote proximity between a membrane-bound target protein and a membrane-localized E3 ubiquitin ligase, directing the target toward lysosomal degradation. This approach enables selective elimination of previously undruggable cell-surface proteins with tissue-specific precision. Founded by the Oncode Institute alongside the Oncode Bridge Fund and Argobio Studio, Laigo Bio initially focuses on oncology — targeting novel immune-oncology markers and intractable oncogenic drivers — with planned expansion into immunology and neuroinflammation. The company completed an oversubscribed seed round of €11.5M in late 2024, attracting backing from Angelini Ventures and Cancer Research Horizons.